Si-Bone, Inc. (SIBN) Stock Price & Analysis
Si-Bone, Inc. (SIBN) rose 3.74% to USD 15.53 as of June 10, 2026 at 03:30 UTC, according to Nexqual real-time market data.
SIBN last closed at USD 14.97; the session ranged USD 14.94–15.57 on volume of 322,824 shares. Market capitalization is $688.74M, with a 52-week range of USD 11.48–21.89 (NGM). Source: Nexqual, June 10, 2026 at 03:30 UTC.
Key Statistics (as of June 10, 2026 at 03:30 UTC)
| Price | USD 15.53 |
|---|---|
| Change | ▲ 3.74% (up) |
| Previous Close | USD 14.97 |
| Open | USD 14.96 |
| Day Range | USD 14.94 – 15.57 |
| 52-Week Range | USD 11.48 – 21.89 |
| Volume | 322,824 shares |
| Market Cap | $688.74M |
| Exchange | NGM |
Technical Analysis (SIBN)
Nexqual's technical model rates SIBN "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 03:30 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.01 (neutral) |
| vs SMA50 | Above (USD 13.76) |
| MACD | 0.36 (positive) |
Analyst Ratings (SIBN)
Wall Street analysts rate SIBN "Strong Buy" based on 8 analysts, with a mean price target of USD 24.13 (range USD 18–32), per Nexqual as of June 10, 2026 at 03:30 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 24.13 |
| High Target | USD 32 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (SIBN)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $55.33M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.1 vs est -0.19 ▲ beat |
| 2025-12-31 | USD -0.04 vs est -0.13 ▲ beat |
| 2025-09-30 | USD -0.11 vs est -0.17 ▲ beat |
| 2025-06-30 | USD -0.14 vs est -0.18 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
Financials & Fundamentals (SIBN)
| Total Revenue | $206.22M |
|---|---|
| Revenue Growth (YoY) | +11.20% |
| Gross Margin | +79.59% |
| Operating Margin | -9.69% |
| Profit Margin | -8.10% |
| ROE | -9.64% |
| Debt / Equity | 24 |
| Current Ratio | 9.99 |
| Total Cash | $144.68M |
| Total Debt | $42.95M |
| Free Cash Flow | $-2.65M |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
Financial Health Score (SIBN)
Nexqual rates Si-Bone, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:30 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 80%, operating -10% |
| Balance Sheet | Strong — $145M cash vs $43M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$3M, burning cash |
| Efficiency | Critical — ROE -10%, ROA -5.3% |
Ownership (SIBN)
| Insider Ownership | +3.29% |
|---|---|
| Institutional Ownership | +108.08% |
| Shares Outstanding | 44.35M |
| Float | 42.83M |
| Short % of Float | +15.48% |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
Leadership (SIBN)
Si-Bone, Inc. is led by Laura A. Francis (age 58), CEO & Director, per Nexqual as of June 10, 2026 at 03:30 UTC.
| CEO & Director | Laura A. Francis (age 58) |
|---|---|
| Executive Chairman | Jeffrey W. Dunn (age 69) |
| COO & CFO | Anshul Maheshwari (age 45) |
| Senior VP of Engineering & CTO | Scott A. Yerby (age 57) |
| Vice President of Financial Planning & Analysis and Investor Relations | Saqib Iqbal |
Major Backers & Investors (SIBN)
Notable institutional backers of Si-Bone, Inc. include First Light Asset Management, LLC, American Century Companies Inc, Brown Advisory Inc., according to Nexqual as of June 10, 2026 at 03:30 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Light Asset Management, LLC | 12.07% |
| American Century Companies Inc | 9.94% |
| Brown Advisory Inc. | 4.79% |
| Cadian Capital Management, LP | 4.26% |
| Granahan Investment Management LLC | 3.92% |
| Impax Asset Management Group plc | 3.21% |
| IMPAX FUNDS SERIES TRUST I-Impax Small Cap Fund | 3.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.77% |
| Vanguard Group | 7.86% |
| Nuveen | 2.9% |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
From Si-Bone, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally.
- It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.
- The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KIDS | OrthoPediatrics Corp. | USD 18.49 | ▲ 0.93% |
| VREX | Varex Imaging Corporation | USD 10.62 | ▲ 5.25% |
| QTRX | Quanterix Corporation | USD 3.09 | ▼ 6.36% |
| LIVN | LivaNova PLC | USD 77.17 | ▲ 6.65% |
| LUNG | Pulmonx Corporation | USD 1.53 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:30 UTC. This page is informational and not investment advice.